J&J/Actavis recall US lots of fentanyl patches

25 February 2008

US health care major Johnson & Johnson says that all US lots of 25mcg/hr Duragesic (fentanyl transdermal system), CII patches sold by PriCara, and all 25mcg/hr patches sold by Sandoz, are being voluntarily recalled from wholesalers and pharmacies as a precaution. The withdrawn lots all expire on or before December 2009, and all are made by Alza Corp, an affiliate of J&J's PriCara. All 25mcg/hr patches manufactured by Alza and sold in Canada are also being recalled.

In separate news, Icelandic generic drugmaker Actavis says that its US unit has recalled 14 lots of its fentanyl transdermal painkiller from wholesalers and pharmacies as a precaution. The patches were manufactured by Corium International, a contract manufacturer for Actavis, and sold nationwide by Actavis South Atlantic. The firm stressed that its fentanyl patches sold in Europe are not affected. According to the US Food and Drug Administration, the recalled lots may have a fold-over defect which may cause the patch to leak and expose patients or caregivers directly to the fentanyl gel. Although unaware of any injuries resulting from this issue, Actavis is withdrawing these lots. The agency noted on its web site that exposure to fentanyl gel may lead to serious adverse events, including respiratory depression and possible overdose.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >




Today's issue

Company Spotlight